Latest News

Vernalis Announces Corvus Pharmaceuticals, Inc. as its Worldwide Licensee for their Adenosine Antagonist Program

Adenosine antagonists under development for use in immuno-oncology

Vernalis plc ("Vernalis" or the "Company") today announces Corvus Pharmaceuticals, Inc. ("Corvus") as its licensee for their adenosine antagonist program.

Read more ...

At a glance

More information on Vernalis and it's pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form